Positron Attends 49th Annual Scientific Session of the American College of Cardiology.

Business Editors

HOUSTON--(BUSINESS WIRE)--March 20, 2000

Mobile P.E.T. Introduces First Mobile Cardiac Pet Service With

Positron Posicam HZ PET Scanner 

Positron Corporation (OTC BB: POSC) announced today that it attended the annual American College of Cardiology (ACC) meeting in Anaheim, California held March 12-15 in association with Mobile P.E.T. Systems, Inc. and Bracco Diagnostics. Positron featured its Posicam HZ PET scanners with Mobile P.E.T. Systems. The 49th annual Scientific Session of the ACC was attended by more than 30,000 medical professionals from around the world and featured studies on positron emission tomography (PET).

Paul J. Crowe, CEO and President of Mobile P.E.T. Systems, said, "We are very pleased to be developing a service for the delivery of mobile, cardiac dedicated PET scanning. Positron Corporation is a pioneer in clinical PET imaging and the leader in cardiac PET scanning. Our association with Positron and Bracco, developers of a portable Rubidium 82 (Cardiogen) system, will allow us to provide improved patient care and the management of coronary artery disease. We look forward to working Positron and Bracco in the future to develop this unique service."

Gary Brooks, President of Positron, stated, "Positron was pleased to have an opportunity to showcase its Posicam HZ Series PET scanner in conjunction with Mobile P.E.T. Systems and Bracco Diagnostics at the ACC meeting. Our strong presence in the cardiology market should serve us well as we work with Mobile P.E.T. Systems to offer the first mobile, cardiac dedicated PET scanning services. We were encouraged by the domestic and international interest in PET and Positron at the ACC meeting."

Mobile P.E.T. Systems, Inc. provides PET services to hospitals and other healthcare providers on a contractual basis. Mobile P.E.T.'s services include the PET imaging technology, FDG Radiopharmaceuticals, and physician over-read services providing a total solution approach to PET for interim, or long term shared services.

Positron Corporation is primarily engaged in designing, manufacturing, marketing and supporting advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM(tm) systems. POSICAM(tm) systems incorporate patented and proprietary technology for the diagnosis and treatment of patients in the areas of oncology, cardiology and neurology. POSICAM(tm) systems are in use at leading medical facilities, including the Cleveland Clinic Foundation, Yale University/Veterans Administration, Crawford Long Hospital, Hadassah Hebrew University Hospital in Jerusalem, Israel, Hermann Hospital and the University of Madrid.

Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements which are other than statements of historical facts. Certain statements contained herein are forward-looking statements and, accordingly, involve risks and uncertainties which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company's expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, including, without limitations, management's examination of historical operating trends, data contained in the Company's records and other data available from third parties, but there can be no assurance that management's expectations, beliefs or projections will result or be achieved or accomplished. In addition to other factors and matters discussed elsewhere herein, the following are important factors that, in the view of the Company, could cause actual results to differ materially from those discussed in the forward-looking statements: the ability of the Company to attain widespread market acceptance of its POSICAM(tm) systems; the ability of the Company to obtain acceptable forms and amounts of financing to fund future operations; demand for the Company's services; and competitive factors. The Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.